Microbot Medical Inc. (MBOT) Stock

About Microbot Medical Inc.

Microbot Medical Inc. is led by CEO Harel Gadot, publicly traded since 1992.

Microbot Medical Inc. (MBOT) stock trades at $0.97 with a market capitalization of $65.41M. The stock is valued at a negative price-to-earnings (P/E) ratio of -4.45, reflecting a net loss over the last twelve months, price-to-book of 1.13, price-to-sales of 152.78. Over the past 52 weeks the stock has ranged between $0.94 and $3.46, and currently trades 72.0% below its 52-week high.

On profitability, Microbot Medical Inc. generates a return on equity (ROE) of -21.87% (negative, reflecting a net loss), return on capital employed of -26.64%, an operating margin of -152.78%, a net profit margin of -94.21%.

Microbot Medical Inc. by the numbers, 2016–2025

Between 2016 and 2025 Microbot Medical Inc. reported revenue of $0 rising to $0. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit fell to $-13.0M.

The most recent net margin is -94.21%. On a trailing twelve-month basis to Jun '26, revenue is $0 and net profit $-17.0M.

Borrowings stand at $1.0M, cash from operations was $-13.0M in the latest year, positive in 0 of the last 10.

Return on equity has averaged -155.2% over five years, and was -16.7% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Microbot Medical Inc. (MBOT) — frequently asked questions